In the United States Court of Federal Claims
                              OFFICE OF SPECIAL MASTERS
                                  (Filed: October 16, 2013)

* * * * * * * * * * * * * *                 *
SAURABH V. AMIN and ARCHANA                 *      UNPUBLISHED
AMIN, natural parents and guardians of      *
SHEAA AMIN, a minor,                        *      No. 13-300V
                                            *
              Petitioners,                  *      Special Master Dorsey
                                            *
v.                                          *
                                            *      Attorneys’ fees denied; reasonable basis,
SECRETARY OF HEALTH                         *      Pneumococcal polysaccharide vaccine;
AND HUMAN SERVICES,                         *      Pneumovax; vaccine not covered.
                                            *
              Respondent.                   *
* * * * * * * * * * * * * * *
Carol L. Gallagher, Carol L. Gallagher, Esquire, LLC, Linwood, NJ, for petitioners.
Lynn E. Ricciardella, U.S. Department of Justice, Washington, DC, for respondent.

                DECISION DENYING ATTORNEYS’ FEES AND COSTS1

        On April 29, 2013, petitioners filed a petition under the National Vaccine Injury
Compensation Program (“Vaccine Act”)2 alleging that their daughter, Sheaa Amin (“Sheaa”), at
nine years of age, suffered an adverse reaction after receiving the pneumococcal polysaccharide
vaccine called Pneumovax 23.3 Petition (“Pet.”) at 1.

       1
          Because this decision contains a reasoned explanation for the undersigned’s action in
this case, the undersigned intends to post it on the United States Court of Federal Claims’
website, in accordance with the E-Government Act of 2002, Pub. L. No. 107-347, 116 Stat.
2899, 2913 (Dec. 17, 2002). As provided by Vaccine Rule 18(b), each party has 14 days within
which to request redaction “of any information furnished by that party: (1) that is a trade secret
or commercial or financial in substance and is privileged or confidential; or (2) that includes
medical files or similar files, the disclosure of which would constitute a clearly unwarranted
invasion of privacy.” Vaccine Rule 18(b). Otherwise, “the entire” decision will be available to
the public. 

National Vaccine Injury Compensation Program is set forth in Part 2 of the
National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755, codified as
amended, 42 U.S.C. §§ 300aa-1 to -34 (2006) (“Vaccine Act”). All citations in this order to
individual sections of the Act are to 42 U.S.C. § 300aa.
       3
         Pneumovax is a polysaccharide-type pneumococcal vaccine indicated for the
prevention of pneumococcal disease caused by 23 serotypes. HIGHLIGHTS OF PRESCRIBING
INFORMATION, PNEUMOVAX 23 1 (2013).
                                                 1
         Petitioners alleged that on March 21, 2011, Sheaa was “administered the Pneumovax 23
vaccine to her right deltoid muscle.” Pet. at 1; Pet’rs’ Ex. 4B at 103. Following her vaccination,
Sheaa experienced “an allergic reaction [with] tongue swelling and episodes of hot flashes
accompanied by vertiginous sensations of spinning, bifrontal headache, and seeing ‘double or
triple.’” Pet. at 1.

      Petitioners were denied compensation because the Pneumovax vaccine is not listed in the
Vaccine Injury Table. Amin v. Sec’y of Health & Human Servs., No. 13-300, 

, *2 (Fed. Cl. Spec. Mstr. July 29, 2013).

       Under the Vaccine Act, when petitioners fail to establish that they are entitled to
compensation, special masters enjoy discretion to award petitioners reasonable attorneys’ fees
and costs. When compensation is not awarded,

       The special master or court may award an amount of compensation to cover
       petitioner’s reasonable attorneys’ fees and other costs incurred in any proceeding
       on such petition if the special master or court determines that the petition was
       brought in good faith and there was a reasonable basis for the claim for which the
       petition was brought.

42 U.S.C. § 300aa-15(e)(1)(emphasis added).

         On August 23, 2013, petitioners filed a motion seeking a total award of $12,149.86, for
their attorneys’ fees and costs pursuant to 42 U.S.C. § 300aa-15(e). Petitioners’ application for
fees did not include a brief in support of their application or any type of argument that the court
has jurisdiction to award attorneys’ fees in a case where the petition did not concern a vaccine
listed on the Vaccine Injury Table. A petitioner must establish subject matter jurisdiction before
attorneys’ fees and costs may be awarded. See Brice v. Sec’y of Health & Human Servs., 

, 1370 (Fed. Cir. 2001), overruled in part by Cloer v. Sec’y of Health & Human Servs.,

, 1340 (Fed. Cir. 2011) (en banc).

        Although the petition in this case was not dismissed on jurisdictional grounds, other
special masters have dismissed cases that involved a vaccine that was not covered under the
Vaccine Act. See Nutt v. Sec’y of Health & Human Servs., No. 10-862V, 

(Fed. Cl. Spec. Mstr. Feb. 23, 2011) (dismissing petition involving the Pneumovax vaccine for
lack of subject matter jurisdiction); Morrison v. Sec’y of Health & Human Servs., No. 04-1683,

(Fed. Cl. Spec. Mstr. July 26, 2005) (same).

        The question of subject matter jurisdiction need not be answered in this case in order to
determine whether petitioners are entitled to an award of attorneys’ fees and costs. Petitioners
are not eligible for an award of attorneys’ fees and costs in this case because they have not
established a reasonable basis for bringing the petition. Although the “reasonable basis”
standard is typically construed in a liberal manner, special masters have required, at a minimum,
that the vaccine be listed on the Vaccine Injury Table. See Schmidt v. Sec’y of Health & Human


http://www.merck.com/product/usa/pi_circulars/p/pneumovax_23/pneumovax_pi.pdf.
Servs., No. 11-401, 

, *1 (Fed. Cl. Spec. Mstr. Mar. 2012); Rydzewski v. Sec’y
of Health & Human Servs., No. 99-571V, 

(Fed. Cl. Spec. Mstr. Jan. 29,
2008); Dover v. Sec’y of Health & Human Servs., No. 99-2299V, 

(Cl. Ct. Spec.
Mstr. Feb. 14, 1992).

        In addition, the undersigned notes that petitioners’ counsel previously brought a similar
claim under the Vaccine Act involving the same vaccine. See Schmidt, 

, *1
(Fed. Cl. Spec. Mstr. Mar. 2012). The petition in that case was dismissed because the vaccine
(identical to the vaccine alleged in this case) was not listed in the Vaccine Injury Table. 

petitioner in the Schmidt case was denied her request for attorneys’ fees and costs
because the special master found that the petition lacked a reasonable basis. 

are required prior to the filing of any paper under the Vaccine Act. Di
Roma v. Sec’y of Health & Human Servs., No. 90-3277, 

, *1 (Fed. Cl. Spec.
Mstr. Nov. 1993) (“Indeed, the chief characteristic of the court’s not finding a reasonable basis
for a claim is where fundamental inquiries are not made.”) In this case, a minimal investigation
would have revealed the absence of any legal or medical support for petitioners’ claim. Section
11(c)(1) of the Vaccine Act clearly requires that the injured person have “received a vaccine set
forth in the Vaccine Injury Table …” This unambiguous requirement eliminates any possibility,
and therefore reasonableness, of a claim for compensation based on this particular vaccine.
Indeed, petitioners’ counsel’s own prior experience in attempting to adjudicate a petition that
involved the same vaccine should have informed counsel that this claim could not proceed.
Given the complete lack of support for this claim, the undersigned sees no possible basis for
finding a reasonable basis.

        Petitioners’ request for attorneys’ fees and costs is DENIED. The Clerk’s Office is
instructed to enter judgment in accordance with this decision unless a motion for review is filed.

       IT IS SO ORDERED.

                                             s/Nora Beth Dorsey
                                             Nora Beth Dorsey
                                             Special Master




                                                 3